|
GB202019954D0
|
|
Treatment regimens for early idiopathic Parkinson's Disease
|
|
GB202016425D0
|
|
Treatment regimens for parkinson's disease
|
|
GB202011709D0
|
|
Solid dispersion of opicapone
|
|
GB202003705D0
|
|
Micronised opicapone
|
|
GB201908044D0
|
|
Dopamine-B-Hydroxylase inhibitors
|
|
GB201810395D0
|
|
Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
|
|
GB201804439D0
|
|
Dopamin-b-hydroxylase inhibitors
|
|
WO2016083863A1
|
|
Medicaments for slowing parkinson's disease
|
|
AU2014296894A1
|
|
Urea compounds and their use as FAAH enzyme inhibitors
|
|
CN105793247A
|
|
Imidazolecarboxamides and their use as FAAH inhibitors
|
|
GB201409466D0
|
|
Urea compounds and their use as enzyme inhibitors
|
|
GB201408594D0
|
|
New salts
|
|
GB201401198D0
|
|
Process for the syntheis of substituted urea compounds
|
|
KR20150084022A
|
|
1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
|
|
GB201316410D0
|
|
Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
|
|
GB201313903D0
|
|
Urea compounds and their use as enzyme inhibitors
|
|
GB201313786D0
|
|
Urea compounds and their use as enzyme inhibitors
|
|
GB201313204D0
|
|
Urea compound and its use as an enzyme inhibitor
|
|
GB201313203D0
|
|
Urea compound and its use as an enzyme inhibitor
|
|
BR112015001546A2
|
|
urea compounds and their use as enzyme inhibitors
|
